BioSpace News Archive

Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced financial results for the quarter ended March 31, 2023, and highlighted recent corporate accomplishments.

Precision X-Ray, Inc., a global leader in cabinet X-ray irradiators, is excited to announce the launch of CellRadHD, our next generation high-dose benchtop irradiator with integrated dosimetry and dose control.

Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC), today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Tuesday, May 9, 2023.

Actinium Pharmaceuticals, Inc. today announced that the Company’s management team will participate in 1x1 meetings and deliver a corporate presentation on Monday, May 15, 2023 at 3:20 PM EST at the Guggenheim Healthcare Talks Radiopharmaceuticals Day.

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will make a cash interest payment of approximately $6.2 million due on June 1, 2023 under its Convertible Senior Secured Notes Indenture.

Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the quarter ended March 31, 2023, and provided a business update.

Virpax ® Pharmaceuticals, Inc. today announced that it has been invited to present its Molecular Envelope Technology (MET), as well as its AnQlar TM product candidate for viral inhibition that utilizes MET, at the June 8, 2023, virtual CB Tech Watch Seminar.

ADC Therapeutics SA (NYSE: ADCT) today announced that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 16th at 10:00 a.m. EDT.

The Insight Partners published latest research report on “Neurotoxin Market Outlook Report, Size, Share, Trends & Growth to 2028 - COVID-19 Impact and Global Analysis By Product Type, Application, and End User”, the global market size is expected to reach USD 13,195.06 million by 2028 from USD 6,622.36 million in 2022; it is estimated to record a CAGR of 12.3% from 2023 to 2028.

Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer and investor in a wide-range of leading-edge, proprietary diagnostic and medical device technologies, is pleased to announce that the Company has established collaborations with several Tuberculosis (TB) medical care facilities to initiate the data collection and screening of active respiratory challenged patients.